A study of chorea after tetrabenazine withdrawal in patients with Huntington disease

Clinical Neuropharmacology

Volumn 31, Issue 3, 2008, Pages 127-133

  Frank, Samuel ^a,g   Ondo, William ^b   Fahn, Stanley ^c   Hunter, Christine ^b   Oakes, David ^d   Plumb, Sandra ^d   Marshall, Frederick ^d   Shoulson, Ira ^d   Eberly, Shirley ^d   Walker, Francis ^e   Factor, Stewart ^f   Hunt, Vicki ^e   Shinaman, Aileen ^d   Jankovic, Joseph ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NEUROLOGICAL INSTITUTE   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NONE   (United States)

Author keywords

Chorea; Huntington disease; Tetrabenazine

Indexed keywords

DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; QUETIAPINE; TETRABENAZINE;

ADULT; AGED; ANXIETY; APPETITE; ARTICLE; AUTOMUTILATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; HALLUCINATION; HUMAN; HUNTINGTON CHOREA; INSOMNIA; MALE; MOOD CHANGE; OBSESSION; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESTLESSNESS; SIDE EFFECT; SLEEP DISORDER;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; CHOREA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TETRABENAZINE; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 41249090997     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3180ca77ea     Document Type: Article

References (25)

1. Frank SA, Marshall F, Plumb S, et al. CARE-HD Investigators of the Huntington Study Group. Functional decline due to chorea in Huntington's disease. Neurology 2004;62(suppl 5):A204.
2. Jankovic J. Huntington's disease. In: Noseworthy J, ed. Neurological Therapeutics: Principles and Practice. London, England: Martin Dunitz; 2006.
3. Dalb- MA. Effect of tetrabenazine on extrapyramidal movement disorders. Br Med J 1969;2(654):422-423.
4. Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv Neurol 1983;37:277-289.
5. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988;38(3):391-394.
6. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48(2):358-362.
7. Marsden CD. Drug treatment of diseases characterized by abnormal movements. Proc R Soc Med 1973;66(9):871-873.
8. Paleacu D, Giladi N, Moore O, et al. Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 2004;27(5):230-233.
9. Fahn S. Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents. Adv Neurol 1983;37:267-276.
10. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 2006;6(1):7-17.
11. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66(3):366-372.
12. Bagchi SP. Differential interactions of phencyclidine with tetrabenazine and reserpine affecting intraneuronal dopamine. Biochem Pharmacol 1983;32(19):2851-2856.
13. Butcher LL, Anden NE. Effects of apomorphine and amphetamine on schedule-controlled behavior: reversal of tetrabenazine suppression and dopaminergic correlates. Eur J Pharmacol 1969;6(3):255-264.
14. Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther 1959;127:103-109.
15. Scherman D, Jaudon P, Henry JP. Binding of a tetrabenazine derivative to the monoamine transporter of the chromaffin granule membrane [In French]. C R Seances Acad Sci III 1981;293(4):221-224.
16. Young AB, Shoulson I, Penney JB, et al. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology 1986;36(2):244-249.
17. Bruyn G. Huntington's chorea. Historical, clinical and laboratory synopsis. In: Vincken P, Bruyn G, eds. Diseases of the Basal Ganglia. Handbook of Clinical Neurology. Amsterdam, Netherlands: North Holland Publishing; 1968:298-378.
18. Hayden M. Huntington's chorea. London, England: Springer Verlag; 1981.
19. Storey E, Beal MF. Neurochemical substrates of rigidity and chorea in Huntington's disease. Brain 1993;116(pt 5):1201-1222.
20. Ondo WG, Tintner R, Thomas M, et al. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol 2002;25(6):300-302.
21. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11(2):136-142.
22. Huntington Stud- Group. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. Neurology 1998;50(5):1366-1373.
23. Fahn S, Elton RL. Members of the UPDRS Developmental Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al, eds. Recent Development in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.
24. Hahn RA. The nocebo phenomenon: concept, evidence, and implications for public health. Prev Med 1997;26(5):607-611.
25. Roberts MS, McLean S, Millingen KS, et al. The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders. Eur J Clin Pharmacol 1986;29(6):703-708.